Olstein Capital Management L.P. boosted its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 30.8% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 119,700 shares of the medical equipment provider’s stock after purchasing an additional 28,200 shares during the period. Olstein Capital Management L.P.’s holdings in Hologic were worth $4,392,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Norinchukin Bank The lifted its position in Hologic by 7.4% during the third quarter. Norinchukin Bank The now owns 20,876 shares of the medical equipment provider’s stock valued at $766,000 after purchasing an additional 1,445 shares in the last quarter. Renaissance Group LLC lifted its position in Hologic by 5.4% during the third quarter. Renaissance Group LLC now owns 776,201 shares of the medical equipment provider’s stock valued at $28,479,000 after purchasing an additional 39,547 shares in the last quarter. Meiji Yasuda Asset Management Co Ltd. lifted its position in Hologic by 43.4% during the third quarter. Meiji Yasuda Asset Management Co Ltd. now owns 20,147 shares of the medical equipment provider’s stock valued at $739,000 after purchasing an additional 6,100 shares in the last quarter. Cipher Capital LP lifted its position in Hologic by 57.9% during the third quarter. Cipher Capital LP now owns 117,673 shares of the medical equipment provider’s stock valued at $4,317,000 after purchasing an additional 43,146 shares in the last quarter. Finally, SG Americas Securities LLC lifted its position in Hologic by 107.6% during the third quarter. SG Americas Securities LLC now owns 34,916 shares of the medical equipment provider’s stock valued at $1,281,000 after purchasing an additional 18,096 shares in the last quarter. Institutional investors own 97.72% of the company’s stock.

Several equities analysts have recently commented on HOLX shares. Needham & Company LLC restated a “buy” rating and issued a $50.00 price objective on shares of Hologic in a research report on Monday, October 2nd. Deutsche Bank AG lowered their price objective on Hologic from $51.00 to $49.00 and set a “buy” rating on the stock in a research report on Thursday, August 3rd. Goldman Sachs Group, Inc. (The) downgraded Hologic from a “conviction-buy” rating to a “buy” rating and lowered their price objective for the company from $48.00 to $47.00 in a research report on Thursday, August 3rd. Stifel Nicolaus restated a “buy” rating and issued a $45.00 price objective (down from $48.00) on shares of Hologic in a research report on Monday, October 9th. Finally, Jefferies Group LLC restated a “buy” rating and issued a $44.00 price objective (down from $49.00) on shares of Hologic in a research report on Tuesday, October 10th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and nine have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $47.54.

In other news, Director Lawrence M. Levy sold 7,139 shares of Hologic stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $39.04, for a total value of $278,706.56. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Elaine Ullian sold 9,282 shares of Hologic stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $40.50, for a total value of $375,921.00. The disclosure for this sale can be found here. Insiders sold 35,972 shares of company stock worth $1,385,977 over the last ninety days. Insiders own 0.79% of the company’s stock.

Shares of Hologic, Inc. (HOLX) traded up $0.28 during mid-day trading on Thursday, hitting $40.88. The stock had a trading volume of 3,276,200 shares, compared to its average volume of 2,739,760. Hologic, Inc. has a 1 year low of $35.76 and a 1 year high of $46.80. The company has a quick ratio of 0.61, a current ratio of 0.79 and a debt-to-equity ratio of 0.78. The company has a market capitalization of $11,192.75, a PE ratio of 20.10, a price-to-earnings-growth ratio of 1.96 and a beta of 0.93.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.49 by $0.01. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The firm had revenue of $802.90 million for the quarter, compared to analysts’ expectations of $792.54 million. During the same period in the previous year, the firm posted $0.52 earnings per share. The business’s revenue was up 10.5% compared to the same quarter last year. research analysts forecast that Hologic, Inc. will post 2.12 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Olstein Capital Management L.P. Has $4.39 Million Position in Hologic, Inc. (HOLX)” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/olstein-capital-management-l-p-has-4-39-million-position-in-hologic-inc-holx/1722189.html.

Hologic Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.